Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Research reports from Johnson & Johnson provide new insights into acute myeloid leukemia
April 27th, 2008
According to a study from the United States, "At present, there is no method available to predict response to farnesyltransferase inhibitors (FTIs). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib in older adults with previously untreated acute myeloid leukemia (AML)." "The RASGRP1/APTX gene expression ratio was found to predict response to tipifarnib with the greatest accuracy using a ''leave one out'' cross validation (LOOCV; 96%). RASGRP1 is a guanine nucleotide exchange factor that activates RAS, while APTX (aprataxin) is involved in DNA excision repair. The utility of this classifier for predicting...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-27)
|
